- 1 Title: Trends in SARS-CoV-2 seroprevalence among pregnant women attending first antenatal care visits
- 2 in Zambia: a repeated cross-sectional survey, 2021-2022
- 3
- 4 Authors: Elizabeth Heilmann^{1,2}, Tannia Tembo³, Sombo Fwoloshi⁴, Bupe Kabamba⁵, Felix Chilambe⁶,
- 5 Kalubi Kalenga³, Mpanji Siwingwa⁶, Conceptor Mulube⁵, Victoria Seffren⁷, Carolyn Bolton-Moore³, John
- 6 Simwanza², Samuel Yingst², Ruchi Yadav⁷, Eric Rogier⁷, Andrew F. Auld², Simon Agolory⁷, Muzala Kapina⁸,
- 7 Julie R. Gutman⁷, Theodora Savory³, Chabu Kangale⁵, Lloyd B. Mulenga⁴, Izukanji Sikazwe^{3,†}, Jonas Z.
- 8 Hines^{2,*,†}
- 9

10 Affiliations:

- 11 1. Public Health Institute, Oakland, CA, USA
- 12 2. U.S. Centers for Disease Control and Prevention, Lusaka, Zambia
- 13 3. Centre for Infectious Disease Research in Zambia, Lusaka, Zambia
- 14 4. Ministry of Health, Lusaka, Zambia
- 15 5. PATH, Lusaka, Zambia
- 16 6. University Teaching Hospital, Lusaka, Zambia
- 17 7. U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA
- 18 8. Zambia National Public Health Institute, Lusaka, Zambia
- 19
- 20 * Corresponding author
- 21 ⁺These authors contributed equally to this report

- 22
- 23 Corresponding author:
- 24 Jonas Hines
- 25 Email: jhines1@cdc.gov
- 26 Address: Centers for Disease Control and Prevention, 351 Independence Ave, Lusaka, Zambia
- 27
- 28 Keywords: COVID-19/epidemiology; COVID-19 Serological Testing; SARS-CoV-2; Seroepidemiologic
- 29 Studies; Public Health Surveillance; Epidemiology/trends; Pregnant Women; Zambia; Africa

31 Abstract

Background SARS-CoV-2 serosurveys help estimate the extent of transmission and guide allocation of
COVID-19 vaccines. We measured SARS-CoV-2 seroprevalence among women attending ANC clinics to
assess exposure trends over time in Zambia. *Methods* We conducted repeated cross-sectional surveys among pregnant women aged 15-49 years
attending their first ANC visits in four districts of Zambia (two urban and two rural) during September
2021-September 2022. Serologic testing was done using a multiplex bead assay which detects IgG

- 38 antibodies to the nucleocapsid protein and the spike protein receptor-binding domain (RBD). We
- 39 calculated monthly SARS-CoV-2 seroprevalence by district. We also categorized seropositive results as
- 40 infection alone, infection and vaccination, or vaccination alone based on COVID-19 vaccination status
- 41 and anti-RBD and anti-nucleocapsid test results.
- 42 Findings Among 8,304 participants, 5,296 (63.8%) were cumulatively seropositive for SARS-CoV-2
- 43 antibodies. SARS-CoV-2 seroprevalence primarily increased from September 2021 to September 2022 in
- 44 three districts (Lusaka: 61.8-100.0%, Chongwe: 39.6-94.7%, Chipata: 56.5-95.0%), but in Chadiza,
- 45 seroprevalence increased from 27.8% in September 2021 to 77.2% in April 2022 before gradually
- 46 dropping to 56.6% in July 2022. Among 5,906 participants with a valid COVID-19 vaccination status,
- 47 infection alone accounted for antibody responses in 77.7% (4,590) of participants.
- 48 Interpretation Most women attending ANC had evidence of prior SARS-CoV-2 infection and most SARS-
- 49 CoV-2 seropositivity was infection-induced. Capturing COVID-19 vaccination status and using a multiplex
- 50 bead assay with anti-nucleocapsid and anti-RBD targets facilitated distinguishing infection-induced
- 51 versus vaccine-induced antibody responses during a period of increasing COVID-19 vaccine coverage in
- 52 Zambia. Declining seroprevalence in Chadiza may indicate waning antibodies and a need for booster

- 53 vaccines. ANC clinics have a potential role in ongoing SARS-CoV-2 serosurveillance and can continue to
- 54 provide insights into SARS-CoV-2 antibody dynamics to inform near real-time public health responses.

56 Introduction

57	SARS-CoV-2 was first detected in Zambia on March 18, 2020. ¹ Since then, the Zambia National Public
58	Health Institute (ZNPHI) has reported nearly 350,000 COVID-19 cases over four main epidemic waves. ²
59	Confirmed case counts underreport the true extent of SARS-CoV-2 infections due to the high proportion
60	of subclinical infections, limited testing supplies, and surveillance gaps. SARS-CoV-2 seroprevalence
61	studies can help bridge the gap in understanding SARS-CoV-2 transmission. In Zambia, a survey of six
62	districts found a pooled prevalence of 10.6% in July 2020 and estimated that 92 infections occurred for
63	every reported case. ³ Another study conducted in a peri-urban district in February 2021 measured a
64	seroprevalence of 33.7%. ⁴ No studies have been published measuring SARS-CoV-2 seroprevalence in
65	Zambia following the Delta and Omicron waves.
66	Repeated cross-sectional surveys leveraging existing healthcare platforms can help monitor trends in
67	seroprevalence during ongoing transmission while minimizing implementation costs associated with
68	large-scale household surveys. Antenatal care (ANC) clinics have been utilized in several countries in
69	Africa to monitor SARS-CoV-2 seroprevalence in a healthy population of women accessing healthcare
70	services. ⁵⁻⁹ In Ethiopia, SARS-CoV-2 surveillance conducted in ANC clinics between April 2020 and March
71	2021 first detected SARS-CoV-2 antibodies in June 2020 and peaked at 11.8% in February 2021. 10
72	Repeated cross-sectional serosurveys in ANC clinics in Kenya found that most women were seropositive
73	for SARS-CoV-2 antibodies by October 2021. ¹¹
74	Early SARS-CoV-2 serosurveys measured antibodies to estimate total infections, but COVID-19 vaccine
75	rollout now clouds seroprevalence interpretations. Detectable antibodies may be the result of SARS-

76 CoV-2 infection, COVID-19 vaccination, or both. Serologic assays with nucleocapsid and spike targets in

- combination with COVID-19 vaccination history can distinguish these groups in countries, like Zambia,
- 78 where most vaccines administered target the spike protein.¹² COVID-19 vaccines first became publicly

79	available in Zambia in April 2021. ¹³ After a slow rollout initially, the Ministry of Health announced
80	achieving 70% coverage of the targeted population on November 1, 2022. ¹⁴ Most COVID-19 vaccine
81	doses received and distributed in Zambia have been the spike-targeting Janssen (61%) and Pfizer-
82	BioNTech (20%) vaccines. ¹³
83	In Zambia, 97% of women attend at least one ANC visit during pregnancy, and antenatal attendees have
84	long served as a sentinel population for HIV, syphilis, and malaria surveillance. ¹⁵⁻¹⁷ Whether this platform
85	can be leveraged to monitor COVID-19 remains unknown. We aimed to estimate monthly
86	seroprevalence of SARS-CoV-2 antibodies among pregnant women attending first antenatal care visits at
87	selected health facilities in four districts of Zambia from September 2021 to September 2022.
88	
89	Methods
90	Study setting and population
91	We conducted repeated cross-sectional surveys of women attending first ANC visits in four districts
92	(Chadiza, Chipata, Chongwe, and Lusaka) of Zambia from September 2021 to September 2022. Data
93	collection began after Zambia's third epidemic wave caused by the Delta variant (May-August 2021) and
94	encompassed the fourth COVID-19 wave driven by the Omicron variant (December 2021-March 2022).
95	The four districts were purposefully selected to capture a range of urban (Chipata and Lusaka) and rural

96 (Chadiza and Chongwe) communities and districts with points-of-entry into Zambia (e.g., international

97 airport in Lusaka and land borders with Malawi and Mozambique in Chipata and Chadiza, respectively).

- 98 A sample size of 200 women per district per month was selected based on available resources and an
- 99 acceptable margin of error for the expected range of SARS-CoV-2 seroprevalence estimates over the
- 100 study period. Ten facilities per district were randomly selected using probability proportional to the

average number of ANC enrollments per month among health facilities reporting an average of at least 101 102 19 antenatal enrollments per month in 2020. Each facility in Chipata, Chongwe, and Lusaka districts 103 enrolled up to 20 participants per month among pregnant women aged 15-49 years attending their first 104 ANC visits. A health worker provided information on the study during group counseling sessions when 105 the health facility provided routine first-time ANC services. Pregnant women willing to participate were 106 screened for eligibility and, if consenting, were enrolled in the study until 20 participants were recruited 107 per facility each month. In Chadiza District, all women attending the first ANC were approached for 108 participation as part of a larger malaria surveillance pilot project, and up to 200 samples were selected 109 post-enrollment for SARS-CoV-2 serologic testing per month.¹⁸ (For months with >200 participants in 110 Chadiza, within each month, records were ordered by facility and interview date and the first 20 111 participants' specimens were tested for SARS-CoV-2. If a facility had fewer than 20 participants in a 112 month, specimens from other sites in Chadiza were selected and tested based on interview date until 113 the sample size of 200 was reached.) SARS-CoV-2 surveillance in Chadiza goes until July 2022 (instead of 114 September 2022) when the malaria surveillance project ended. At all sites, women were screened for 115 acute COVID-19 prior to enrollment, and those exhibiting symptoms were referred for COVID-19 testing 116 and case management per government protocols and excluded from the study.

117 Data collection and sample processing

Participants were administered an electronic questionnaire on tablets using the Open Data Kit platform (Get ODK Inc., San Diego, CA, USA) to gather demographic data, SARS-CoV-2 exposures, COVID-19 vaccination, and routine ANC test results (i.e., HIV, syphilis, hepatitis, and malaria). Possible SARS-CoV-2 exposures included participants or households prior positive SARS-CoV-2 test and sustained close contact with a suspected or known COVID-19 case. COVID-19 vaccination and prior COVID-19 statuses were self-reported. Study staff attempted to verify COVID-19 vaccination information from vaccination cards if participants had them available on the day of their ANC visit. From February 2022 onward,

participants self-reported inter-district and international travel, frequency of visits to churches, funerals
 or weddings, markets, and indoor dining, and use of public transportation and face masks to provide a
 general sense of COVID-19 risk behaviors.

128 Whole blood was collected on filter paper as dried blood spots (DBS) using the same finger prick or 129 venipuncture from routine ANC testing. HIV, syphilis, hepatitis B, and malaria tests were conducted 130 according to national guidelines, subject to the availability of test kits. Chipata, Chongwe, and Lusaka 131 district specimens were transported to a central laboratory for testing at University Teaching Hospital 132 (Lusaka, Zambia) and Chadiza District specimens were transported to PATH laboratory (Lusaka, Zambia) 133 for testing. Serologic testing was done using the FlexImmArray SARS-CoV-2 Human IgG Antibody Test 134 (Tetracore Inc, Rockville, MD, USA) on the MAGPIX platform (Luminex Corp, Austin, TX, USA) according 135 to manufacturer instructions with DBS preparation as described by Tartof et al.¹⁹⁻²⁰ The assay was 136 verified in-country in conjunction with the US CDC prior to its use. This multiplex bead assay has three 137 SARS-CoV-2 targets: nucleocapsid (N) protein, the receptor binding domain (RBD) of the spike-1 protein, 138 and a N-RBD fusion protein. Signal ratios were calculated for each target as the median fluorescent 139 intensity of the protein divided by the average calibrator median fluorescent intensity from each plate. 140 Samples with signal ratios ≥1.2 for all three targets were considered SARS-CoV-2 IgG positive with past 141 SARS-CoV-2 exposure, and samples with a signal ratio ≤0.9 for any target were considered SARS-CoV-2 142 IgG negative. Signal ratios >0.9 and <1.2 were considered indeterminate and the samples were re-run. 143 Valid results of the second test were retained in the final dataset. Samples with indeterminate results after re-testing were categorized as SARS-CoV-2 IgG negative. Samples with persistent quality control 144 145 issues were removed from the final dataset.

146 Statistical analysis

147	SARS-CoV-2 seroprevalence was estimated as the number of positive cases divided by the total number
148	of tests with valid results by month and district. Seroprevalence was adjusted based on the assay
149	sensitivity (89.8%) and specificity (100.0%) from an independent test. ²¹ Trend analysis was conducted to
150	compare SARS-CoV-2 seroprevalence with district-level COVID-19 case reports provided by ZNPHI. ²
151	District-level populations exposed to SARS-CoV-2 were calculated using 2022 Census population
152	projection estimates from the Zambia Statistics Agency and peak SARS-CoV-2 seroprevalence estimates
153	during data collection. ²² These peak estimates of persons exposed to SARS-CoV-2 were compared to the
154	total number of reported COVID-19 cases at the end of the study to estimate the ratio of reported cases
155	to total SARS-CoV-2 infections in each district.
156	In a sub-analysis, target-specific assay results and COVID-19 vaccination status were analyzed to group
157	antibody responses into no evident response (anti-RBD negative), infection only (anti-RBD positive,
158	unvaccinated), vaccination only (anti-RBD positive, vaccinated, anti-N negative), or vaccination and
159	infection (anti-RBD positive, vaccinated, anti-N positive) based off the decision tree developed by Duarte
160	et al. ¹² Antibody responses in participants who received an unknown or inactivated virus vaccine were
161	classified as indeterminate. Wilcoxon rank sum tests were used to compare signal ratios for each assay
162	target by antibody response category. Logistic regression controlling for enrollment month was used to
163	identify factors associated with seropositivity and calculate adjusted odds ratios. Sub-analyses were
164	conducted among participants who reported prior confirmed COVID-19 and those who had received a
165	COVID-19 vaccine. Analyses were conducted using R version 4.2.1 (R Foundation for Statistical
166	Computing, Vienna, Austria).

167

168 Results

- 169 Between September 2021 and September 2022, 9,221 pregnant women attending their first ANC visits
- were enrolled. A total of 8,558 (92.8%) samples were tested; among those, 8,304 (97.0%) valid SARS-
- 171 CoV-2 antibody results were matched to participant questionnaires (Chadiza: 1,616, Chipata: 2,099,
- 172 Chongwe: 2,441, Lusaka: 2,148). Two-hundred and fifty four specimens could not be linked to
- 173 questionnaire data, so were not included in the analysis.

174 The median age of participants was 25 years (interquartile range [IQR]: 20-30; supplementary table 1).

175 The majority (57.9%) of participants achieved primary education or less and most were unemployed

176 (40.2%) or farmers (24.9%). Only 2.2% of women reported having COVID-19 prior to study enrollment,

177 3.3% reported confirmed COVID-19 in the household, and 3.9% reported close contact with a confirmed

178 or suspected COVID-19 case outside the household. About half of participants responded that they wore

a mask all or most of the time in public (49.5%) or were observed to be wearing a face mask properly

180 during the ANC visit (49.3%). Vaccination coverage of one or more COVID-19 vaccine doses increased

181 from 4.4% in September 2021 to 26.6% in September 2022. Most vaccinated women (1,274/1,688) had

received the Janssen vaccine and 87.4% were considered fully vaccinated with the primary series.

183 Routine ANC testing for syphilis and hepatitis B was reported in less than half of participants (40.2% and

184 11.7%, respectively), but most (96.7%) women were tested for HIV or knew their HIV status prior to the

185 visit and 8.8% were positive.

186 Overall, 5,296 (63.8%) participants were SARS-CoV-2 seropositive. Seroprevalence was highest in Lusaka

- and lowest in Chadiza throughout the study period (figure 1). In Lusaka, SARS-CoV-2 adjusted
- seroprevalence rose from 61.8% (95% confidence interval [CI]: 52.8-70.5%) in September 2021 to
- 189 100.0% in August and September 2022 (August 95% CI: 97.2-100.0; September 95% CI: 100.0-100.0).

190 SARS-CoV-2 seroprevalence also peaked near 100% in August 2022 in Chipata (97.3% [91.7-100.0]) and 191 Chongwe (96.8% [91.9-100.0]) districts but dropped slightly in September 2022 (95.1% [89.0-99.7] and 192 94.7% [89.6-98.8], respectively). In Chadiza, SARS-CoV-2 seroprevalence peaked at 77.2% (95% Cl: 61.8-193 78.6) in April 2022 and then gradually dropped to 56.6% (95% CI: 46.7-66.5) when data collection ended 194 in July 2022. The greatest single month increase in urban districts (Lusaka and Chipata) was from 195 December 2021 to January 2022 during the peak of the Omicron wave in Zambia, while in rural districts 196 (Chadiza and Chongwe), the greatest increases were seen in March and April 2022, respectively. 197 In the sub-analysis exploring target-specific assay results and COVID-19 vaccination status, 6,042 (72.8%) were positive for anti-RBD IgG and 6,343 (76.4%) were positive for anti-N IgG. Overall, 2,053 (24.7%) 198 199 participants had no detectible antibodies to the RBD or nucleocapsid proteins, and 345 (4.2%) were 200 indeterminate (supplementary figure 1). Among 5,906 participants with anti-RBD antibodies and a valid 201 COVID-19 vaccination status, most (77.7%) were likely infection-induced only, 20.6% from vaccination 202 and infection, and only 1.6% vaccination-induced alone. Infection-induced antibodies were the most 203 common throughout the study period while hybrid infection and vaccination antibody responses 204 became more common over time (figure 2). In Chadiza, hybrid antibodies surpassed infection-induced 205 starting in April 2022. In comparing target-specific signal ratios by antibody response category, no 206 difference was observed for the nucleocapsid target (figure 3). For the RBD target, the median signal 207 ratio was significantly higher among participants who were vaccinated and infected compared to 208 participants who were infected or vaccinated alone, and the median signal ratio for participants who were only infected was greater than for those who were only vaccinated. 209 210 Pairwise logistic regression adjusting for enrollment month identified different factors associated with 211 SARS-CoV-2 serostatus in each district (table 1). Women aged 40-49 years in Chipata had nearly three 212 times the odds of seropositivity compared to women aged 15-19 years (aOR: 2.76 [95% CI: 1.16-6.58]),

but age was not significantly associated with serostatus elsewhere. In Chadiza and Chongwe districts,

women who had completed secondary education or higher had greater odds of SARS-CoV-2

- seropositivity compared to women with some primary education (Chadiza aOR: 1.76 [1.17-2.64];
- 216 Chongwe aOR: 1.64 [1.16-2.31]). Significant differences were observed in SARS-CoV-2 seroprevalence by
- 217 occupation in all districts except Chadiza. In Chipata, women living with HIV (WLHIV) had higher odds of
- seropositivity compared to HIV-negative women (aOR: 1.42 [1.05-1.90]), although this association was
- no longer significant after further adjusting for age group (aOR: 1.29 [0.95-1.76]).
- 220 SARS-CoV-2 seropositivity was significantly associated with prior confirmed COVID-19 only in Chadiza
- 221 (aOR=3.06 [1.55-6.07]; table 1). Among 179 reported prior COVID-19 cases, 130 (72.6%) were SARS-CoV-
- 222 2 seropositive at the time of enrollment. The median time between COVID-19 diagnosis and first ANC
- visit was 9 months (IQR: 7-14) among women who tested SARS-CoV-2 seropositive and 8 months (IQR:
- 4-13) among seronegative women (p = 0.13).
- 225 COVID-19 vaccination was associated with significantly higher odds of SARS-CoV-2 seropositivity in all
- four districts, adjusting for enrollment month (table 1). Among vaccinated women, SARS-CoV-2
- serostatus did not differ by partial vs. full primary vaccine series or vaccine type (table 2). Compared to
- women who received their first COVID-19 vaccine dose within one month prior to study enrollment,
- 229 participants who received their first dose one to five months prior had greater odds of testing SARS-CoV-

230 2 seropositive, controlling for enrollment month and district (aOR: 1.58 [1.19-2.10]).

231 Twenty-one percent of the 179 participants with prior COVID-19 reported being hospitalized.

- Hospitalization and time between COVID-19 and enrollment were not associated with SARS-CoV-2
- serostatus, but COVID-19 vaccination was associated with greater odds of seropositivity among these
- women (OR: 4.32 [2.07-9.02]; table 3).
- 235 District-level cumulative incidence was calculated from 2022 population projections and reported
- 236 COVID-19 cases from March 2020 through the end of the survey (July 2022 for Chadiza and September

2022 elsewhere) and ranged from 1.1% in Chadiza District to 3.5% in Lusaka District (table 4). Overall,
90,150 COVID-19 cases were reported in the four districts from March 2020 to September 2022 but we
estimated that 2,911,393 people had evidence of SARS-CoV-2 exposure. The ratio of SARS-CoV-2
seroprevalence to cumulative incidence was 29:1 in Lusaka District, 31:1 in Chadiza District, 39:1 in
Chipata District, and 92:1 in Chongwe District.

242

243 Discussion

244 SARS-CoV-2 seroprevalence was high among participants and nearly all first ANC attendees in three out 245 of four study districts had evidence of SARS-CoV-2 infection. In those districts, seroprevalence generally 246 increased over the 13-month study period, while in Chadiza, it declined from April to July 2022. Lower 247 seroprevalence in Chadiza District was expected, being the most rural of the study districts. The very 248 high seroprevalence in Lusaka District was also expected given a study conducted at two Lusaka 249 hospitals which found that 36.9% of women attending ANC clinics between March and July 2021 (part of 250 the Delta wave, prior to this study) were positive for SARS-CoV-2 by RT-PCR.²³ The large rise in SARS-251 CoV-2 seroprevalence from November 2021 to March 2022 when the Omicron wave occurred was 252 similar to what was seen in South Africa where seroprevalence among the general population was 73% before the Omicron wave and 91% after.²⁴⁻²⁵ This high seroprevalence was proposed as a reason for the 253 254 lack of significant transmission waves after Omicron, despite the emergence of Omicron sub-lineages with greater infectivity and low COVID-19 vaccine coverage.²⁵ 255 256 COVID-19 vaccination among participants was low and most SARS-CoV-2 antibodies were likely 257 infection-induced. COVID-19 vaccination was associated with higher odds of SARS-CoV-2 seropositivity

and COVID-19 vaccination in combination with SARS-CoV-2 infection produced the strongest immune

response, both of which could be explained by a robust immune response caused by hybrid immunity.²⁶

260 Other studies in Africa also measured higher SARS-CoV-2 seroprevalence among vaccinated participants, 261 higher neutralizing antibody titers among participants with infection and vaccination, and faster waning 262 of antibodies post-vaccination among participants who had not been infected.^{7,27-29} These results 263 support the recommendation for COVID-19 vaccination (including booster doses) regardless of past 264 infection. COVID-19 vaccination campaigns were conducted throughout Zambia during the study period, 265 but vaccine coverage among study participants was lower than the general population, possibly 266 reflecting hesitancy toward vaccination during pregnancy, and only about 12% of the fully vaccinated 267 population has received a booster dose.² COVID-19 messages and risk mitigation strategies addressing 268 the concerns of pregnant women can be incorporated seamlessly into routine ANC to prevent adverse 269 outcomes in this population at higher risk for severe COVID-19. Healthcare providers can screen for 270 symptoms of COVID-19, malaria, and tuberculosis simultaneously, and COVID-19 vaccines may be 271 administered alongside tetanus boosters. 272 The ratios of SARS-CoV-2 seroprevalence to cumulative incidence were lower than the 1:92 ratio 273 previously measured in a July 2020 serosurvey in other parts of Zambia.³ This reduction mirrors the 274 downward global trend in seroprevalence to cumulative incidence ratios since 2020 (i.e., improving case 275 detection ratios) and may be due to evolving testing strategies and increased availability and use of 276 rapid antigen test kits.³⁰ Interpretation of these ratios late in the pandemic is complicated by 277 reinfections, waning antibodies, and non-report of home RDT results, leading to an underestimation of 278 total SARS-CoV-2 infections. Some past SARS-CoV-2 infections may not be detectable as antibodies wane 279 over time and people with asymptomatic infections or mild clinical cases may mount less of an immune 280 response.³¹ This is consistent with the women who were SARS-CoV-2 seronegative despite reporting 281 prior COVID-19 and may explain the declining seroprevalence observed in some districts and months. 282 Older age, higher education, and urban versus rural location were all associated with higher 283 seroprevalence during the July 2020 survey in Zambia, and similar associations were noted in some

284 districts during this study.³ This may reflect differences in access to COVID-19 information and infection 285 prevention supplies or in the ability to comply with COVID-19 risk mitigation guidelines among certain 286 subpopulations. These factors may intersect with occupation which was also associated with differences 287 in seroprevalence in most districts. Diverse work environments, such as open fields for farming, compact 288 cubicles in an office, or crowded market stalls, could impact an individual's SARS-CoV-2 exposure risk. 289 Similar associations were noted in Mozambique where market sellers and those engaged in formal employment had higher SARS-CoV-2 seroprevalence than other community members.²⁹ Furthermore, 290 291 modes of transportation might vary by urban/rural status, which could in turn affect risk of coming into 292 contact with SARS-CoV-2. Tailored COVID-19 prevention messaging for demographic groups with higher 293 SARS-CoV-2 seroprevalence may help reduce transmission during future waves. These observed 294 differences in SARS-CoV-2 prevalence by certain demographic groups could simply reflect differences in 295 COVID-19 risk for different groups in the population. 296 Most COVID-19 mitigation strategies in Zambia were carried out nationally by the Ministry of Health. 297 Given the differences in SARS-CoV-2 risk factors and seroprevalence trends by district, subnational 298 strategies may be more suitable in the future to mitigate COVID-19 risk where and when needed. 299 District or provincial level responses could help direct resources to areas of high transmission while 300 avoiding imposing strict measures in areas with low transmission where the social and economic 301 burdens of mitigation efforts may outweigh the benefit of reducing transmission. This approach was 302 used to lift masking requirements in Zambia as districts reached 70% vaccination coverage and 303 demonstrates that robust surveillance systems and quality tracking of key COVID-19 indicators at the 304 district level can facilitate subnational decision-making.³² 305 This study has several limitations. First, we could not estimate a single population-weighted

306 seroprevalence because of the non-systematic selection of districts and participants. Our study was

307 limited to women aged 15-49 years and may not be representative of populations that may be more or

308 less susceptible to SARS-CoV-2 infection. However, a global meta-regression analysis found no 309 difference in seroprevalence by sampling frame comparing studies among pregnant women to 310 household and community surveys.³⁰ As with all SARS-CoV-2 seroprevalence surveys, our estimates 311 depend on serologic test performance. The manufacturer's requirement of testing positive for all three 312 targets for an overall positive sample is more conservative than single target assays and may have 313 excluded some past infections. Waning of SARS-CoV-2 antibodies might have resulted in 314 underestimation of seroprevalence, and variability in the waning time for different antibody types could 315 have biased the sub-analysis findings categorizing infection/vaccination statuses. Studies have shown that anti-nucleocapsid antibodies wane more quickly than anti-spike antibodies, ³³⁻³⁴ although anti-N 316 317 antibody prevalence was slightly greater than anti-RBD antibody prevalence in our study. Adjusting the 318 seroprevalence estimates based on a test sensitivity of 90% likely helped but the potential for 319 misclassification remains. Given the cross-sectional study design, we could not assess whether those 320 who were seronegative had truly never been exposed to SARS-CoV-2, had been exposed and never 321 mounted a detectable antibody response, or had sero-reverted before testing. Lastly, we were uncertain 322 how the premature ending of SARS-CoV-2 surveillance in Chadiza in July 2022 affected the overall 323 seroprevalence estimates for this study. 324 Despite these limitations, our study also has notable strengths. We measured SARS-CoV-2 325 seroprevalence over 13 months which encompassed periods before, during, and after Zambia's Omicron 326 wave. The study period also spanned early COVID-19 vaccine rollout in Zambia, and the use of a 327 multiplex bead assay with spike and nucleocapsid targets allowed us to distinguish seropositivity from 328 infection versus vaccination. We included several districts which had not been included in previous 329 SARS-CoV-2 seroprevalence studies and found substantial geographic variation, particularly in the most 330 rural study district. Finally, we demonstrated the feasibility of integrating SARS-CoV-2 serosurveillance 331 into routine health services which may be adaptable to future epidemics.

- As the COVID-19 pandemic continues to evolve, so does the role of seroprevalence studies. While our
- 333 study shows that most people living in Zambia have likely been exposed to SARS-CoV-2, seroprevalence
- 334 studies may still play a valuable role in understanding waning population immunity over time and
- 335 susceptibility to emerging variants. Longitudinal cohort studies may be better suited than cross-sectional
- 336 surveys to meet these needs, and ANC may continue to be a useful platform for recruiting participants
- as women attend frequent follow-up visits during pregnancy and postpartum periods.

339 Author Contributions: EH, TT, SF, BK, CBM, SY, JRG, VS, LM, IS, and JZH designed the study. TT, BK, and 340 KK monitored data and sample collection, transport, and storage. FC, MS, and CM performed the lab 341 analysis, and VS, RY, and ER interpreted the lab results. EH, JS, MK, and JZH accessed and verified the 342 underlying data. EH analyzed the data and produced the figures. EH wrote the first draft of the 343 manuscript and all other coauthors reviewed and approved of the final version. All authors had access to 344 the study data and approved the final copy of the manuscript for publication submission. 345 Ethics statement: This study was authorized by the National Health Research Authority (NHRA) through 346 an expedited review of COVID-19 related studies. For Chadiza District, the SARS-CoV-2 data collection 347 and serologic testing were reviewed and approved by the University of Zambia Biomedical Research 348 Ethics Committee as an amendment to a pre-existing malaria surveillance protocol. This activity was 349 reviewed by CDC and was conducted consistent with applicable federal law and CDC policy (See e.g., 45 350 C.F.R. part 46.102(I)(2), 21 C.F.R. part 56; 42U.S.C. §241(d); 5 U.S.C. §552a;44 U.S.C. §3501 et seq). All 351 methods were carried out in accordance with relevant guidelines and regulations. Written informed 352 consent was obtained for all participants before enrollment. Pregnant women under 18 years are 353 considered emancipated minors in Zambia for the purpose of providing their own informed consent. 354 Funding statement: This research was financially supported by the Centers for Disease Control and 355 Prevention (CDC) Emergency Response to the COVID-19 pandemic and the President's Emergency Plan 356 for AIDS Relief (PEPFAR) through the CDC under the terms of cooperative agreements with the Centre 357 for Infectious Disease Research in Zambia (5 NU2GGH002251-02-00) and the Public Health Institute (5 358 NU2GGH002093-05-00). No additional external funding was received for this study. The funders had no 359 role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. 360 Data Availability Statement: The data that support the findings of this study are available from Zambia 361 Ministry of Health, but restrictions apply to the availability of these data, which were used under license

- 362 for the current study, and so are not publicly available. Data are however available from the authors
- 363 upon reasonable request and with permission of Zambia Ministry of Health. Interested researchers
- 364 should submit a research proposal to the CDC Zambia science office at: <u>zm-ads@cdc.gov</u>. If approved,
- the requestor must sign a data use agreement. Additionally, the study protocol is available for request.
- 366 *Competing interests*: The authors have read the journal's policy and have the following competing
- 367 interests: There are no patents, products in development, or marketed products associated with this
- 368 research to declare. The authors have declared that no competing interests exist.
- 369 Authorship Disclaimer: The findings and conclusions in this report are those of the author(s) and do not
- 370 necessarily represent the official position of the U.S. Centers for Disease Control and Prevention.

372 References

- Chipimo PJ, Barradas DT, Kayeyi N, et al. First 100 Persons with COVID-19 Zambia, March 18–April
 28, 2020. *MMWR Morb Mortal Wkly Rep* 2020; **69(42):** 1547–48.
- Zambia National Public Health Institute. Zambia COVID-19 Dashboard. Mar 14, 2023.
 https://www.arcgis.com/apps/dashboards/3b3a01c1d8444932ba075fb44b119b63 (accessed Apr 13, 2023).
- Mulenga LB, Hines JH, Fwoloshi S, et al. Prevalence of SARS-CoV-2 in six districts in Zambia in July,
 2020: a cross-sectional cluster sample survey. *Lancet Glob Health* 2021; **9**: e773–81.
- Shanaube K, Schaap A, Klinkenberg E, et al. SARS-CoV-2 seroprevalence and associated risk factors in periurban Zambia: a population-based study. *Int J Infect Dis* 2022; **118**: 256–63.
- National Institute for Communicable Diseases. SARS-CoV-2 seroprevalence in the Cape Town
 Metropolitan Subdistricts after the peak of infections. COVID-19-Special-Public-Health-Surveillance Bulletin_Issue-5.pdf (accessed May 15, 2023).
- Otieno NA, Azziz-Baumgartner E, Nyawanda BO, et al. SARS-CoV-2 infection among pregnant and
 postpartum women, Kenya, 2020-2021. *Emerg Infect Dis* 2021; **27(9):** 2497–99.
- Abdullahi A, Oladele D, Owusu M, et al. SARS-CoV-2 antibody responses to AZD1222 vaccination in
 West Africa. *Nat Commun* 2022; **13**: 6131.
- Sawry S, Le Roux J, Wolter N, et al. High prevalence of SARS-CoV-2 antibodies in pregnant women
 after the second wave of infections in the inner-city of Johannesburg, Gauteng Province, South
 Africa. Int J Infect Dis 2022; 125: 241–49.
- Gonzalez R, Nhampossa T, Figueroa-Romero A, et al. SARS-CoV-2 seropositivity and HIV viral load
 among Mozambican pregnant women. *J Acquir Immune Defic Syndr* 2023; **92(2):** 115–21.
- Assefa N, Regassa LD, Teklemariam Z, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in women
 attending antenatal care in eastern Ethiopia: a facility-based surveillance. *BMJ Open* 2021; 11:
 e055834.
- 11. Lucinde RK, Mugo D, Bottomley C, et al. Sero-surveillance for IgG to SARS-CoV-2 at antenatal care
 clinics in three Kenyan referral hospitals: Repeated cross-sectional surveys 2020-21. *PLoS ONE* 2022;
 17(10): e0265478.
- 400 12. Duarte N, Yanes-Lane M, Arora RK, et al. Adapting serosurveys for the SARS-CoV-2 vaccine era. *Open* 401 *Forum Infect Dis* 2021; https://doi.org/10.1093/ofid/ofab632.
- 402 13. UNICEF. COVID-19 Market Dashboard. Dec 21, 2020. https://www.unicef.org/supply/covid-19 403 market-dashboard (accessed Jun 12, 2023).
- 404 14. Lusaka Times. Zambia celebrates 770 percent COVID-19 vaccination achievement. Nov 2, 2022.
- https://www.lusakatimes.com/2022/11/02/zambia-celebrates-70-percent-covid-19-vaccination achievement/ (accessed Jun 12, 2023).

407 15. Zambia Statistics Agency. Zambia demographic and health survey 2018. Jan 2020.

- 408 https://www.zamstats.gov.zm/download/5400/?tmstv=1684233605&v=5436 (accessed Sep 25, 2020).
- 412 national surveillance. *Sex Transm Dis* 2012; **39(3):** 173–81.
- 413 17. Gutman JR, Mwesigwa JN, Arnett K, et al. Using antenatal care as a platform for malaria surveillance
 414 data collection: study protocol. *Malar J* 2023; 22: 99.
- 415 18. Kangale C, Musunse M, Phiri-Chibawe C, et al. Routine malaria prevalence and intervention
 416 coverage estimates obtained by surveying antenatal care (ANC) attendees in Chadiza District,
 417 Eastern Province, Zambia: progress and lessons learned. ASTMH 2020. LB-5073
- 418 19. Tetracore Inc. Instructions for use: Tetracore FlexImmArray SARS-CoV-2 Human IgG Antibody Test.
 419 https://tetracore.com/wp-content/uploads/2021/04/FlexImmArraySARS-CoV-
- 420 2lgGkitIFU_ver05122020_web.pdf (accessed Jan 9, 2023).
- 20. Tartof SY, Xie F, Yadav R, et al. Prior SARS-CoV-2 infection and COVID-19 vaccine effectiveness
 against outpatient illness during widespread circulation of SARS-CoV-2 omicron variant, US Flu VE
 Network. *medRxiv* 2023; published online Jan 11, 2023.
 https://doi.org/10.1101/2023.01.10.23284397 (proprint)
- 424 https://doi.org/10.1101/2023.01.10.23284397 (preprint).
- 425 21. Mitchell KF, Carlson CM, Nace D, et al. Evaluation of a multiplex bead assay against single-target
 426 assays for detection of IgG antibodies to SARS-CoV-2. *Microbiol Spectr;* 10(3):
 427 https://doi.org/10.1128/spectrum.01054-22.
- 22. Zambia Statistics Agency. 2022 census of population and housing preliminary report. Dec 2022.
 https://www.zamstats.gov.zm/download/5578/?tmstv=1684233605&v=9742 (accessed Feb 14, 2023).
- 431 23. Lubeya MK, Kabwe JC, Mukosha M, et al. Maternal COVID-19 infection and associated factors: A
 432 cross-sectional study. *PLoS ONE* 2023; **18(3)**: e0281435.
- 433 24. Madhi SA, Kwatra G, Myers JE, et al. Population immunity and COVID-19 severity with Omicron
 434 variant in South Africa. *N Engl J Med* 2022; **386:** 1314–26.
- 435 25. Madhi SA, Kwatra G, Myers JE, et al. Sustained low incidence of severe and fatal COVID-19 following
 436 widespread infection induced immunity after the Omicron (BA.1) dominant in Gauteng, South
 437 Africa: An observational study. *Viruses* 2023; **15(3)**: 597.
- 438 26. Altarawneh HN, Chemaitelly H, Ayoub HH, et al. Effects of previous infection and vaccination on
 439 symptomatic Omicron infections. *N Engl J Med* 2022; **387:** 21–34.
- 440 27. Awandu SS, Ochieng AO, Onyango B, et al. High seroprevalence of Immunoglobulin G (IgG) and IgM
 441 antibodies to SARS-CoV-2 in asymptomatic and symptomatic individuals amidst vaccination roll-out
 442 in western Kenya. *PLoS ONE* 2022; **17(12):** e0272751.

- 443 28. Konu YR, Conde S, Gbeasor-Komlanvi F, et al. SARS-CoV-2 antibody seroprevalence in Togo: a 444 national cross-sectional household survey, May-June, 2021. BMC Public Health 2022; 22: 2294. 445 29. Arnaldo A, Mabunda N, Young PW, et al. Prevalence of severe acute respiratory syndrome 446 coronavirus 2 (SARS-CoV-2) antibodies in the Mozambican population: a cross-sectional serologic 447 study in 3 cities, July-August 2020. Clin Infect Dis 2022; 75(S2): S285-93. 448 30. Bergeri I, Whelan MG, Ware H, et al. Global SARS-CoV-2 seroprevalence from January 2020 to April 449 2022: A systematic review and meta-analysis of standardized population-based studies. PLoS Med 450 2022; 19(11): e1004107. 31. Yadouleton A, Sander A, Moreira-Soto A, et al. Limited specificity of serologic tests for SARS-CoV-2 451 452 antibody detection, Benin. Emerg Infect Dis 2021; 27(1): 233-37.
- 453 32. Chaponda D. Govt lifts wearing of masks in 22 districts. *News Diggers!* Aug 15, 2022.
- 454 https://diggers.news/local/2022/08/15/govt-lifts-wearing-of-masks-in-22-
- districts/#:~:text=HEALTH%20Minister%20Sylvia%20Masebo%20has,%2C%20Chingola%2C%20Chifu
 nabuli%20and%20Luanshya (accessed May 12, 2023).
- 457 33. Ripperger TJ, Urhlaub JL, Watanabe M, et al. Orthogonal SARS-CoV-2 serological assays enable
 458 surveillance of low-prevalence communities and reveal durable humoral immunity. *Immunity* 2020;
 459 53: 925–33.
- 460 34. Alfego D, Sullivan A, Poirier B, Williams J, Adcock D, Letovsky S. A population-based analysis of the
 461 longevity of SARS-CoV-2 antibody seropositivity in the United States. *EClinicalMedicine* 2021; 36:
 462 100902.

Supplementary table 1. Participant demographics, SARS-CoV-2 exposures and risk behaviors, and ANC test results								
	Chadiza	Chipata	Chongwe	Lusaka	Total			
	n=1616	n=2099	n=2441	n=2148	N=8304			
	n (%)							
Age, median (IQR)	22 (19-28)	25 (21-30)	24 (20-30)	26 (22-30)	25 (20-30)			
15-19	438 (27.1)	369 (17.6)	518 (21.2)	210 (9.8)	1535 (18.5)			
20-29	760 (47.0)	1190 (56.7)	1300 (53.3)	1297 (60.4)	4547 (54.8)			
30-39	251 (15.5)	481 (22.9)	531 (21.8)	576 (26.8)	1839 (22.1)			
40-49	26 (1.6)	43 (2.0)	90 (3.7)	57 (2.7)	216 (2.6)			
Unknown	141 (8.7)	16 (0.8)	2 (0.1)	8 (0.4)	167 (2.0)			
Education								
No education	377 (23.3)	171 (8.1)	77 (3.2)	31 (1.4)	656 (7.9)			
Some primary	779 (48.2)	518 (24.7)	809 (33.1)	413 (19.2)	2519 (30.3)			
Completed primary	133 (8.2)	553 (26.3)	608 (24.9)	337 (15.7)	1631 (19.6)			
Some secondary	200 (12.4)	612 (29.2)	732 (30.0)	805 (37.5)	2349 (28.3)			
Completed secondary or higher	123 (7.6)	240 (11.4)	215 (8.8)	559 (26.0)	1137 (13.7)			
Unknown	4 (0.2)	5 (0.2)	0 (0.0)	3 (0.1)	12 (0.1)			
Occupation		· ·			· · ·			
Farmer	1383 (85.6)	443 (21.1)	602 (24.7)	10 (0.5)	2438 (24.9)			
Daily laborer/pieceworker	8 (0.5)	78 (3.7)	325 (13.3)	64 (3.0)	475 (5.7)			
Merchant/shop owner	12 (0.7)	56 (2.7)	55 (2.3)	108 (5.0)	231 (2.8)			
Health worker	8 (0.5)	16 (0.8)	6 (0.2)	13 (0.6)	43 (0.5)			
Government employee/civil servant	27 (1.7)	47 (2.2)	17 (0.7)	88 (4.1)	179 (2.2)			
Private sector employee	6 (0.4)	31 (1.5)	25 (1.0)	145 (6.8)	207 (2.5)			
Hawker/market seller	14 (0.9)	142 (6.8)	164 (6.7)	241 (11.2)	561 (6.8)			
Student	89 (5.5)	95 (4.5)	79 (3.2)	111 (5.2)	374 (4.5)			
Unemployed	63 (3.9)	996 (47.5)	1088 (44.6)	1195 (55.6)	3342 (40.2)			
Other occupation	1 (0.1)	162 (7.7)	54 (2.2)	162 (7.5)	379 (4.6)			
Unknown	5 (0.3)	33 (1.6)	26 (1.1)	11 (0.5)	75 (0.9)			
Prior COVID-19								
No	1565 (96.8)	2031 (96.8)	2375 (97.3)	2054 (95.6)	8025 (96.8)			
Yes	42 (2.6)	42 (2.0)	31 (1.3)	64 (3.0)	179 (2.2)			
Unknown	9 (0.6)	26 (1.2)	35 (1.4)	30 (1.4)	100 (1.2)			
Household COVID-19					. /			
No	1573 (97.3)	2014 (96.0)	2276 (93.2)	1983 (92.3)	7846 (94.5)			
Yes	36 (2.2)	49 (2.3)	48 (2.0)	137 (6.4)	270 (3.3)			
Unknown	7 (0.4)	36 (1.7)	117 (4.8)	28 (1.3)	188 (2.3)			
Close COVID-19 contact ⁺			(-)	- (- /	(-)			
No	1439 (89.0)	1953 (93.0)	1993 (81.6)	1862 (86.7)	7247 (87.3)			
Yes	30 (1.9)	52 (2.5)	62 (2.5)	176 (8.2)	320 (3.9)			

COVID-19 vaccination [‡] Image: Covid and the second s	8 (0.8)							
No 1089 (67.4) 1633 (77.8) 1925 (78.9) 1904 (88.6) 65 Yes 511 (31.6) 452 (21.5) 486 (19.9) 236 (11.0) 16 Unknown 16 (1.0) 14 (0.7) 30 (1.2) 8 (0.4) 6 Co-infections, positive/tested	5 (20.3) 8 (0.8) 1 (8.8)							
Yes 511 (31.6) 452 (21.5) 486 (19.9) 236 (11.0) 16 Unknown 16 (1.0) 14 (0.7) 30 (1.2) 8 (0.4) 16 Co-infections, positive/tested 48/1586 (3.0) 279/2075 (13.4) 215/2362 (9.1) 164/2008 (8.2) 706/80	5 (20.3) 8 (0.8) 1 (8.8)							
Unknown 16 (1.0) 14 (0.7) 30 (1.2) 8 (0.4) Co-infections, positive/tested	8 (0.8)							
Co-infections, positive/tested 48/1586 (3.0) 279/2075 (13.4) 215/2362 (9.1) 164/2008 (8.2) 706/80	1 (8.8)							
HIV 48/1586 (3.0) 279/2075 (13.4) 215/2362 (9.1) 164/2008 (8.2) 706/80	. ,							
	. ,							
Symphilis 6/956 (0.6) 11/538 (2.0) 7/736 (1.0) 22/1108 (2.0) 46/33	8 (1.4)							
	· /							
Hepatitis B 0/400 (0.0) 0/91 (0.0) 0/41 (0.0) 13/441 (2.9) 13/9	3 (1.3)							
Malaria 190/1616 (11.8) 18/512 (3.5) 6/493 (1.2) 27/464 (5.8) 241/30	5 (7.8)							
COVID-19 risk behaviors [§] n=988 n=1382 n=1690 n=1334 N	5394							
Mask use in public all or most of the time 428 (43.3) 398 (28.8) 755 (44.7) 1090 (81.7) 26	1 (49.5)							
(self-report) 428 (45.5) 598 (26.8) 755 (44.7) 1090 (61.7) 20	1 (49.5)							
Proper mask use during ANC visit 574 (58.1) 429 (31.0) 873 (51.7) 783 (58.7) 26	9 (49.3)							
Travel outside district 41 (4.1) 47 (3.4) 93 (5.5) 100 (7.5) 2	1 (5.2)							
Travel outside Zambia 6 (0.6) 11 (0.8) 5 (0.3) 16 (1.2)	8 (0.7)							
Visit to church or mosque 544 (55.1) 993 (71.9) 1201 (71.1) 886 (66.4) 36	4 (67.2)							
Visit to wedding or funeral 236 (23.9) 698 (50.5) 381 (22.5) 407 (30.5) 17	2 (31.9)							
Visit to market or grocery store 355 (35.9) 1014 (73.4) 1136 (67.2) 1081 (81.0) 35	6 (66.5)							
Indoor dining 64 (6.5) 437 (31.6) 250 (14.8) 352 (26.4) 11	3 (20.4)							
Use of public transportation 77 (7.8) 918 (66.4) 792 (46.9) 989 (74.1) 27	6 (51.5)							
ANC=antenatal care, IQR=interquartile range. [†] Close contact defined as being within 2 meters of someone outside the household suspected or o	nfirmed to							
have COVID-19 for greater than 15 minutes; [‡] ≥1 dose of any COVID-19 vaccine; [§] Responses restricted to February-September 2022								





Figure 1. Reported COVID-19 cases among the general population and SARS-CoV-2 seroprevalence among study
participants, by district. Serologic testing was done using the Tetracore FlexImmArray SARS-CoV-2 Human IgG
Antibody Test; a positive result was assigned if signal ratios ≥1.2 for all 3 assay targets (nucleocapsid [N], receptorbinding domain [RBD] of the spike protein, and N-RBD fusion). Seroprevalence was adjusted for assay performance
(sensitivity=89.8% and specificity=100%) and error bars represent 95% confidence intervals.

471



472

473 Supplementary figure 1. Antibody response categorization based on anti-RBD IgG, anti-nucleocapsid IgG, and

474 COVID-19 vaccination status (N=8,304). The Tetracore FlexImmArray SARS-CoV-2 Human IgG Antibody Test used is

475 a multiplex bead assay with three SARS-CoV-2 targets (i.e., nucleocapsid, receptor-binding domain (RBD) of spike,


476 and fusion) to facilitate distinguishing between infection only, vaccination only, and combined vaccination and

477 infection antibody responses when considered with vaccination history. Participants who reported receiving a

478 Sinopharm or unknown vaccine were categorized as indeterminate due to the inability to distinguish between


479 vaccination only and hybrid vaccination and infection antibody responses from inactivated or attenuated virus

480 vaccines. Adapted from Duarte et al. 2021.



482

Figure 2. SARS-CoV-2 antibody response categorization of study participants by enrollment month and district. No
evident antibody response was defined as testing negative for anti-RBD IgG. Infection-derived antibody response
was defined as positive anti-RBD IgG AND no reported COVID-19 vaccination. Vaccination and infection-derived
hybrid antibody response was defined as positive anti-RBD IgG AND positive anti-nucleocapsid IgG AND reported
COVID-19 vaccination. Vaccination-derived antibody response was defined as positive anti-RBD IgG AND reported
COVID-19 vaccination AND negative anti-nucleocapsid IgG. Equivocal IgG responses, unknown COVID-19
vaccination status, and unknown or Sinopharm vaccine type were categorized as indeterminate.



491

492 Figure 3. Signal ratios for three assay targets by antibody response category. Signal ratios were calculated by

493 dividing the mean fluorescent intensity of the target by the mean fluorescent intensity of the calibrators.

494 Vaccination and infection combined produced the strongest antibody response against all three assay targets

495 compared to infection or vaccination alone. Participants whose antibody response was derived from infection only

496 had greater signal ratios for the RBD target compared to participants with vaccination-derived antibody response

497 only. ns=not significant (p-value>0.05); **p-value<0.001


Table 1. SARS-CoV-2 seropositivity by participant demographics and SARS-CoV-2 exposures and risk behaviors								
		Chadiza Chipata				Chongwe		Lusaka
	SARS-CoV-2 Seropositive	Adjusted Odds Ratio						
	n (%)	aOR 95% CI						
Total	707 (43.8)		1433 (68.3)		1565 (64.1)		1591 (74.1)	
Age								
15-19	182 (41.6)	1 (ref)	244 (66.1)	1 (ref)	330 (63.7)	1 (ref)	154 (73.3)	1 (ref)
20-29	343 (45.1)	1.23 (0.96-1.58)	808 (67.9)	1.12 (0.86-1.46)	823 (63.3)	1.00 (0.80-1.25)	947 (73.0)	0.98 (0.69-1.40)
30-39	114 (45.4)	1.12 (0.80-1.56)	338 (70.3)	1.31 (0.96-1.79)	352 (66.3)	1.21 (0.92-1.59)	443 (76.9)	1.22 (0.83-1.80)
40-49	12 (46.2)	1.43 (0.61-3.33)	36 (83.7)	2.76 (1.16-6.58)*	60 (66.7)	1.17 (0.70-1.95)	42 (73.7)	0.98 (0.48-2.00)
Education								
No education	156 (41.4)	0.91 (0.70-1.18)	108 (63.2)	0.86 (0.59-1.26)	44 (57.1)	1.17 (0.70-1.95)	16 (51.6)	0.44 (0.19-1.00)
Some primary	337 (43.3)	1 (ref)	329 (63.5)	1 (ref)	485 (60.0)	1 (ref)	296 (71.7)	1 (ref)
Completed primary	49 (36.8)	0.96 (0.64-1.43)	390 (70.5)	1.08 (0.82-1.41)	405 (66.6)	1.12 (0.89-1.42)	255 (75.7)	0.91 (0.64-1.30)
Some secondary	95 (47.5)	1.23 (0.88-1.70)	440 (71.9)	1.25 (0.96-1.63)	485 (66.3)	1.34 (1.07-1.67)	602 (74.8)	0.94 (0.70-1.25)
Completed secondary or higher	68 (55.3)	1.76 (1.17-2.64)*	161 (67.1)	1.14 (0.81-1.61)	146 (67.9)	1.64 (1.16-2.31)*	420 (75.1)	0.96 (0.71-1.31)
Occupation								
Farmer	596 (43.1)	0.63 (0.37-1.10)	274 (61.9)	0.66 (0.51-0.85)*	349 (58.0)	0.70 (0.56-0.87)*	9 (90.0)	2.55 (0.30-21.85)
Daily labourer/pieceworker	4 (50.0)	1.20 (0.25-5.81)	49 (62.8)	0.76 (0.46-1.26)	205 (63.1)	0.88 (0.67-1.16)	55 (85.9)	1.93 (0.90-4.15)
Merchant/shop owner	3 (25.0)	0.25 (0.06-1.08)	30 (53.6)	0.55 (0.31-0.98)*	33 (60.0)	1.08 (0.6-1.95)	83 (76.9)	1.94 (1.19-3.18)*
Health worker	4 (50.0)	1.11 (0.24-5.10)	8 (50.0)	0.50 (0.17-1.42)	5 (83.3)	4.70 (0.48-45.97)	10 (76.9)	1.60 (0.40-6.40)
Government/civil servant	13 (48.1)	0.83 (0.32-2.19)	35 (74.5)	1.16 (0.58-2.33)	15 (88.2)	5.02 (1.07-23.47)*	61 (69.3)	0.91 (0.55-1.52)
Private sector employee	3 (50.0)	0.66 (0.11-3.95)	21 (67.7)	0.91 (0.41-2.02)	20 (80.0)	3.38 (1.19-9.58)*	107 (73.8)	1.11 (0.73-1.70)
Hawker/market seller	6 (42.9)	1.05 (0.30-3.67)	102 (71.8)	1.00 (0.67-1.51)	121 (73.8)	1.56 (1.05-2.34)*	181 (75.1)	1.20 (0.86-1.69)
Student	42 (47.2)	0.61 (0.30-1.23)	70 (73.7)	1.16 (0.70-1.91)	54 (68.4)	1.15 (0.69-1.94)	88 (79.3)	0.94 (0.56-1.58)
Unemployed	34 (54.0)	1 (ref)	719 (72.2)	1 (ref)	712 (65.4)	1 (ref)	859 (71.9)	1 (ref)
Other occupation	0 (0.0)		102 (63.0)	0.76 (0.53-1.10)	37 (68.5)	1.24 (0.66-2.33)	129 (79.6)	1.34 (0.87-2.06)
Prior COVID-19								
No	678 (43.3)	1 (ref)	1389 (68.4)	1 (ref)	1525 (64.2)	1 (ref)	1518 (73.9)	1 (ref)
Yes	28 (66.7)	3.06 (1.55-6.07)*	28 (66.7)	0.95 (0.48-1.89)	22 (71.0)	1.68 (0.72-2.95)	52 (81.2)	1.25 (0.64-2.45)
Household COVID-19								
No	684 (43.5)	1 (ref)	1379 (68.5)	1 (ref)	1451 (63.8)	1 (ref)	1458 (73.5)	1 (ref)
Yes	17 (47.2)	1.20 (0.60-2.38)	31 (63.3)	0.95 (0.51-1.77)	36 (75.0)	1.45 (0.71-2.95)	112 (81.8)	1.19 (0.75-1.91)
Close COVID-19 contact ⁺								
No	629 (43.7)	1 (ref)	1348 (69.0)	1 (ref)	1277 (64.1)	1 (ref)	1365 (73.3)	1 (ref)
Yes	11 (36.7)	0.93 (0.42-2.05)	32 (61.5)	0.80 (0.44-1.46)	41 (66.1)	0.95 (0.53-1.67)	140 (79.5)	1.10 (0.73-1.66)
COVID-19 vaccination [‡]								
No	396 (36.4)	1 (ref)	1057 (64.7)	1 (ref)	1164 (60.5)	1 (ref)	1379 (72.4)	1 (ref)
Yes	299 (58.5)	1.76 (1.40-2.21)*	363 (80.3)	1.48 (1.13-1.93)*	381 (78.4)	1.40 (1.09-1.80)*	208 (88.1)	1.97 (1.29-3.02)*


HIV status								
Negative	767 (44.0)	1 (ref)	1212 (67.5)	1 (ref)	1404 (65.4)	1 (ref)	1388 (75.3)	1 (ref)
Positive	16 (33.3)	0.83 (0.43-1.59)	203 (72.8)	1.42 (1.05-1.90)*	113 (52.6)	0.77 (0.57-1.05)	104 (63.4)	0.87 (0.60-1.26)
aOR = adjusted odds ratio (adjusted for enrollment month); CI = confidence interval. [†] Close contact defined as being within 2 meters of someone outside the household suspected or confirmed								
to have COVID-19 for greater than 15 minutes; [‡] ≥1 dose of any COVID-19 vaccine. *p-value<0.05								

Table 2. SARS-CoV-2 seroprevalence among vaccinated participants (n=1685) SARS CoV 2								
	_	SARS-CoV-2		SARS-CoV-2		ted Odds Ratio		
	Serc	positive	Sero	onegative				
	n	(%)	n	(%)	aOR	(95% CI)		
Vaccination status								
Partially vaccinated	123	(70.3)	52	(29.7)	0.74	(0.51-1.07)		
Full primary series	1106	(74.9)	370	(25.1)	1	(ref)		
Vaccine type								
Oxford/AstraZeneca (ChAdOx1-S)	150	(64.9)	81	(35.1)	1	(ref)		
J&J/Janssen (Ad.26.COV2.S)	965	(75.7)	309	(24.3)	1.28	(0.92-1.79)		
Pfizer-BioNTech (BNT162b2)	50	(75.8)	16	(24.2)	0.71	(0.36-1.39)		
Sinopharm	32	(72.7)	12	(27.3)	0.79	(0.37-1.69)		
Mixed	21	(91.3)	2	(8.7)	2.82	(0.60-13.26)		
Other	7	(100.0)	0	(0.0)				
Months between first dose and								
enrollment								
<1 month	290	(69.5)	127	(30.5)	1	(ref)		
1-5 months	669	(75.8)	214	(24.2)	1.58	(1.19-2.10)*		
≥6 months	223	(81.4)	51	(18.6)	1.48	(0.99-2.22)		

Table 3. Characteristics participants reporting prior COVID-19 by SARS-CoV-2 serostatus (n=179)							
	SAR	S-CoV-2	SA	RS-CoV-2	۵dius	ted Odds Ratio	
	Serc	positive	Ser	onegative	Aujus		
	n	(%)	n	(%)	aOR	(95% CI)	
Hospitalized due to COVID-19							
No	100	(78.7)	39	(79.6)	1	(ref)	
Yes	27	(21.3)	10	(20.4)	0.63	(0.24-1.66)	
Months between diagnosis and							
enrollment							
<6 months	20	(18.3)	13	(31.0)	1	(ref)	
6-11 months	41	(37.6)	12	(28.6)	1.02	(0.37-2.79)	
≥12 months	48	(44.0)	17	(40.5)	0.41	(0.11-1.51)	
COVID-19 vaccination ⁺							
No	54	(41.9)	37	(75.5)	1	(ref)	
Yes	75	(58.1)	12	(24.5)	4.11	(1.80-9.41)*	
aOR=adjusted odds ratio (adjusted for district and enrollment month); CI=confidence interval. [†] Received ≥1 doses of							
any COVID-19 vaccine. *p<0.05							

Table 4. Estimated populations exposed to SARS-CoV-2 and ratios of peak seroprevalence to cumulative incidence									
during last survey month									
	Chadiza	Chipata	Chongwe	Lusaka					
Peak SARS-CoV-2 seroprevalence [†]	77.2%	97.3%	96.8%	100.0%					
2022 census population	111,069	327,059	313,389	2,204,059					
Reported COVID-19 cases	2,761	8,096	3,303	75,990					
Cumulative incidence [‡]	2.5%	2.5%	1.1%	3.4%					
Estimated population with evidence of SARS-CoV-2 exposure§	85,745	318,228	303,361	2,204,059					
Ratio of seroprevalence to cumulative incidence31:139:192:129:1									
[†] Peak SARS-CoV-2 seroprevalence for Chadiza District was April	2022; for Chip	ata District, p	eak was Augu	st 2022; for					
Chongwe district, peak was August 2022; for Lusaka District, peak was September 2022. [‡] Calculated as reported cases									
divided by population projection. §Calculated as seroprevalence multiplied by population projection. 2022 census									
data were obtained from the Zambia Statistics Agency and reported COVID-19 cases were obtained from the Zambia									
National Public Health Institute.									





Figure



Indeterminate

No evident response

Infection

Vaccination + Infection

Vaccination



Figure 2





Figure 3



Supplemental Figure 1